Trial Profile
Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2022
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Palbociclib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms NeoPAL
- Sponsors UNICANCER
- 22 Mar 2022 Results (n=106) published in the European Journal of Cancer.
- 04 Jun 2021 Status changed from active, no longer recruiting to completed.
- 11 Sep 2020 This trial has been completed in Belgium, according to European Clinical Trials Database record.